188 related articles for article (PubMed ID: 29284071)
1. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
Xu S; Aguilar A; Xu T; Zheng K; Huang L; Stuckey J; Chinnaswamy K; Bernard D; Fernández-Salas E; Liu L; Wang M; McEachern D; Przybranowski S; Foster C; Wang S
Angew Chem Int Ed Engl; 2018 Feb; 57(6):1601-1605. PubMed ID: 29284071
[TBL] [Abstract][Full Text] [Related]
2. Challenges and opportunities in targeting the menin-MLL interaction.
Cierpicki T; Grembecka J
Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524
[TBL] [Abstract][Full Text] [Related]
3. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong
Xu S; Aguilar A; Huang L; Xu T; Zheng K; McEachern D; Przybranowski S; Foster C; Zawacki K; Liu Z; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2020 May; 63(9):4997-5010. PubMed ID: 32338903
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
6. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
[TBL] [Abstract][Full Text] [Related]
7. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.
Yue L; Du J; Ye F; Chen Z; Li L; Lian F; Zhang B; Zhang Y; Jiang H; Chen K; Li Y; Zhou B; Zhang N; Yang Y; Luo C
Org Biomol Chem; 2016 Sep; 14(36):8503-19. PubMed ID: 27541268
[TBL] [Abstract][Full Text] [Related]
9. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
10. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
11. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).
Borkin D; Pollock J; Kempinska K; Purohit T; Li X; Wen B; Zhao T; Miao H; Shukla S; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2016 Feb; 59(3):892-913. PubMed ID: 26744767
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of menin-MLL interaction and TGF-β signaling induces replication of human pancreatic beta cells.
Pahlavanneshan S; Behmanesh M; Oropeza D; Furuyama K; Tahamtani Y; Basiri M; Herrera PL; Baharvand H
Eur J Cell Biol; 2020 Jun; 99(5):151094. PubMed ID: 32646642
[TBL] [Abstract][Full Text] [Related]
13. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
14. Structure-based screening and optimization of cytisine derivatives as inhibitors of the menin-MLL interaction.
Zhong HJ; Lee BR; Boyle JW; Wang W; Ma DL; Hong Chan PW; Leung CH
Chem Commun (Camb); 2016 Apr; 52(34):5788-91. PubMed ID: 27004852
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface.
Ren J; Xu W; Tang L; Su M; Chen D; Chen YL; Zang Y; Li J; Shen J; Zhou Y; Xiong B
Bioorg Med Chem Lett; 2016 Sep; 26(18):4472-4476. PubMed ID: 27528435
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
17. Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility.
Senter T; Gogliotti RD; Han C; Locuson CW; Morrison R; Daniels JS; Cierpicki T; Grembecka J; Lindsley CW; Stauffer SR
Bioorg Med Chem Lett; 2015 Jul; 25(13):2720-5. PubMed ID: 25987377
[TBL] [Abstract][Full Text] [Related]
18. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.
Borkin D; Klossowski S; Pollock J; Miao H; Linhares BM; Kempinska K; Jin Z; Purohit T; Wen B; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2018 Jun; 61(11):4832-4850. PubMed ID: 29738674
[TBL] [Abstract][Full Text] [Related]
19. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
[TBL] [Abstract][Full Text] [Related]
20. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]